Home › Multiple Myeloma › Florida › Tampa
Pag-aaral pangklinika para sa Multiple Myeloma sa Tampa, FL
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Tampa. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Nagre-recruitPhase 1
- Moffitt Cancer Center /ID# 279068, Tampa
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Tampa
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Moffit Cancer center, Tampa
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Nagre-recruitPhase 4
- Moffitt Cancer Center, Tampa
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Moffitt Cancer Center, Tampa
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Moffitt Cancer Center, Tampa
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Research Site, Tampa
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Tampa
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Tampa
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Nagre-recruitPhase 1/2
- Moffitt Cancer Center /ID# 272628, Tampa
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Nagre-recruitPhase 3
- Moffitt at Memorial Healthcare System, Tampa
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Moffitt Cancer Center - McKinley Drive, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Nagre-recruitPhase 1/2
- Moffitt Cancer Center, Tampa
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Moffitt Cancer Center, Tampa
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA41 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO26 pag-aaral
- Columbus, OH24 pag-aaral
- Rochester, MN24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- St. Louis, MO23 pag-aaral
- Chicago, IL22 pag-aaral
Iba pang pag-aaral sa Tampa
- Non-Small Cell Lung Cancer51 pag-aaral
- Kanser sa Suso43 pag-aaral
- Kanser (lahat ng uri)39 pag-aaral
- Colorectal Cancer33 pag-aaral
- Kanser sa Baga29 pag-aaral
- Acute Myeloid Leukemia29 pag-aaral
- Metastatic Cancer29 pag-aaral
- Kanser sa Pancreas27 pag-aaral
- Kanser sa Ovary20 pag-aaral
- Melanoma19 pag-aaral
- Kanser sa Prostate19 pag-aaral
- Myelodysplastic Syndromes19 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.